Xilio Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Xilio Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- XLO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001840233
- EIN
- 85-1623397
Board of directors
-
Akintunde Olatokumbo Bello · DirectorSince 2025
-
Aoife Brennan · DirectorSince 2024
-
Cheryl R. Blanchard · DirectorSince 2026
-
Christina Rossi · DirectorSince 2023
-
Daniel J. Curran · DirectorSince 2024
-
James Samuel Shannon · DirectorSince 2024
-
Paul J. Clancy · DirectorSince 2023
-
Rene Russo · Director · PRESIDENT AND CEOSince 2023
-
Robert W. Ross · DirectorSince 2023
-
Sara Bonstein · DirectorSince 2023
-
Tomas J. Heyman · DirectorSince 2023
-
Yuan Xu · DirectorSince 2023
Chief executives
Rene Russo
· PRESIDENT AND CEO
Dates unknown
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.6%
-
98.1%
-
98.3%
-
98.3%
Board connections
10 of this board's directors also sit on 16 other boards.
- via Daniel J. Curran
- via Cheryl R. Blanchard
- via Christina Rossi
- via Aoife Brennan
- via Cheryl R. Blanchard
- via Tomas J. Heyman
- via Yuan Xu
- via Paul J. Clancy
- via Tomas J. Heyman
- via Aoife Brennan
- via Sara Bonstein
- via Tomas J. Heyman
- via James Samuel Shannon
- via Robert W. Ross
- via James Samuel Shannon
- via Paul J. Clancy
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $43,950
- 1 purchase by 1 insider
- Sold, last 12 months
- $5,668
- 2 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2026 | James Samuel Shannon Director | Open-market purchase | +5,000 | $8.79 | $43,950 |
| Jan 2, 2026 | Brennan Kevin M. Officer (SVP, FINANCE AND ACCOUNTING) | Open-market sale | −1,826 | $0.64 | $1,169 |
| Jan 2, 2026 | Frankenfield Christopher James Officer (Chief Financial Officer) | Open-market sale | −7,030 | $0.64 | $4,499 |
| Jan 1, 2026 | Luptakova Katarina Officer (CHIEF MEDICAL OFFICER) | Option exercise | +16,625 | — | — |
| Jan 1, 2026 | Brennan Kevin M. Officer (SVP, FINANCE AND ACCOUNTING) | Option exercise | +5,000 | — | — |
| Jan 1, 2026 | Frankenfield Christopher James Officer (Chief Financial Officer) | Option exercise | +19,375 | — | — |
| Jan 1, 2026 | Rene Russo Director, Officer (PRESIDENT AND CEO) | Option exercise | +44,250 | — | — |
| Jun 17, 2025 | James Samuel Shannon Director | Open-market purchase | +25,000 | $0.69 | $17,250 |
| Jun 16, 2025 | James Samuel Shannon Director | Open-market purchase | +45,000 | $0.69 | $31,050 |
| Jun 16, 2025 | Rene Russo Director, Officer (PRESIDENT AND CEO) | Open-market purchase | +36,289 | $0.68 | $24,677 |
| Jan 2, 2025 | Frankenfield Christopher James Officer (Chief Financial Officer) | Open-market sale | −6,954 | $0.98 | $6,815 |
| Jan 2, 2025 | Brennan Kevin M. Officer (SVP, FINANCE AND ACCOUNTING) | Open-market sale | −1,803 | $0.98 | $1,767 |
| Jan 1, 2025 | Frankenfield Christopher James Officer (Chief Financial Officer) | Option exercise | +19,375 | — | — |
| Jan 1, 2025 | Luptakova Katarina Officer (CHIEF MEDICAL OFFICER) | Option exercise | +16,625 | — | — |
| Jan 1, 2025 | Rene Russo Director, Officer (PRESIDENT AND CEO) | Option exercise | +44,250 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.